Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Since its discovery, ADAM17, also known as TNF α converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents for ADAM17 advancing into the clinic. Researchers have now developed potential drugs for ADAM17 that are selective and do not have the side effects which were seen in earlier chemical entities that targeted this enzyme. ADAM17 inhibitors have broad therapeutic potential, with properties ranging from tumor immunosurveillance and overcoming drug and radiation resistance in cancer, as treatments for cardiac hypertrophy and inflammatory conditions such as inflammatory bowel disease and rheumatoid arthritis. This review focuses on substrates and inhibitors identified more recently for ADAM17 and their role in cancer and inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149 · cited 1×
“Initially ADAM17 was identified as a TNF-alpha converting enzyme [6, 7].”
BackgroundIL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018 · cited 2×
“Growth of tumors is prevented in IL-23 or IL-23R knockout mice, and genetic deletion or antibody-mediated elimination of IL23 increases the activity of cytotoxic T cells in a model of chemically induced carcinogenesis [44].”
BackgroundThorp, E., Vaisar, T., Subramanian, M., Mautner, L., Blobel, C., & Tabas, I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.263020 · Cited by 298
Van Schaeybroeck, S., Kalimutho, M., Dunne, P. D., Carson, R., Allen, W., Jithesh, P. V., Redmond, K. L., Sasazuki, T., Shirasawa, S., Blayney, J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.032 · Cited by 106 · cited 2×
“ADAM17 was shown to negatively regulate c-MET signaling by increasing the levels of soluble MET in a KRAS mutant colorectal cancer model [99].”
BackgroundKyula, J. N., Van Schaeybroeck, S., Doherty, J., Fenning, C. S., Longley, D. B., & Johnston, P. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0014 · Cited by 99
Molecular basis for the mechanism of action of an anti‐TACE antibody
Peng, L., Cook, K., Xu, L., Cheng, L., Damschroder, M., Gao, C., Wu, H., & Dall'Acqua, W. F. (2016) · mAbs · doi:10.1080/19420862.2016.1226716 · Cited by 30 · cited 1×
“Another ADAM17 inhibitory antibody (MEDI3622) was recently developed and studied in vitro, ex vivo, and in vivo [146, 147].”
Background
Cited by
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Jin, Y., Ji, W., Yang, H., Chen, S., Zhang, W., & Duan, G. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00454-7 · Cited by 399
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor
Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101305 · Cited by 381
“LAG3 cleavage is mediated by a disintegrin and metalloproteinase domain-containing protein 10 and 17 (ADAM10 and ADAM17), whose activity can also induce the cleavage of other immune receptors such as TNFα, CD62L, TIM3 and VEGFR2 [35].”
BackgroundTargeting Notch in oncology: the path forward
Majumder, S., Crabtree, J. S., Golde, T. E., Minter, L. M., Osborne, B. A., & Miele, L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00091-3 · Cited by 270
Kahveci-Türköz, S., Bläsius, K., Wozniak, J., Rinkens, C., Seifert, A., Kasparek, P., Ohm, H., Oltzen, S., Nieszporek, M., Schwarz, N., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04783-y · Cited by 17
Metadata
- Authors
- Moss, M. L., & Minond, D.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2017
- Volume
- 2017
- Pages
- 1-21
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W2766941260
- Cited by
- 153
- References
- 6
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. https://app.cochat.ai/papers/10.1155/2017/9673537
- The paper
- Moss, M. L., & Minond, D. (2017). Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators of Inflammation. https://doi.org/10.1155/2017/9673537
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.